Allogene Therapeutics (ALLO) Current Deferred Revenue (2020 - 2024)

Allogene Therapeutics has reported Current Deferred Revenue for 5 years, with the latest figure at $86000.0 in Q1 2024.

• Quarterly Current Deferred Revenue changed 0.0% year-over-year to $86000.0 in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $86000.0 (changed 0.0% YoY) and the FY2023 annual result came in at $86000.0, down 9.47% from the prior year.
• Current Deferred Revenue held at $86000.0 in Q1 2024 per ALLO's latest filing, from $86000.0 in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $39.0 million in Q4 2020 and troughed at $86000.0 in Q1 2023.
• A 5-year average of $2.9 million and a median of $101500.0 in 2022 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2021 and 2024: Current Deferred Revenue slumped 99.6% in 2021, then changed 0.0% in 2024.
• Over 5 years, Current Deferred Revenue stood at $39.0 million in 2020, then slumped by 99.6% to $156000.0 in 2021, then tumbled by 39.1% to $95000.0 in 2022, then slipped by 9.47% to $86000.0 in 2023, then changed by 0.0% to $86000.0 in 2024.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $86000.0, $86000.0, and $86000.0 for Q1 2024, Q4 2023, and Q3 2023 respectively.